Clinical Registry of Long-Term Dental Outcomes in Head and Neck Cancer Patients
NCT05325970 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 350
Last updated 2026-02-06
Summary
The current study (ORARAD II) will examine participants of the original cohort for a visit roughly 7 years after the start of RT. The primary outcomes will be the 7-year rate of dental caries, periodontal disease, tooth loss, osteoradionecrosis and salivary flow.
Conditions
- Head and Neck Cancer
- Dental Diseases
- Osteoradionecrosis
Sponsors & Collaborators
-
National Institute of Dental and Craniofacial Research (NIDCR)
collaborator NIH - collaborator OTHER
-
UConn Health
collaborator OTHER - collaborator OTHER
-
Brigham and Women's Hospital
collaborator OTHER - collaborator OTHER
-
University of North Carolina
collaborator OTHER -
Wake Forest University Health Sciences
lead OTHER
Principal Investigators
-
Michael T. Brennan, DDS, MHS · Wake Forest University Health Sciences
-
Rajesh V. Lalla, DDS, PhD · UConn Health
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-02-28
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
Countries
- United States
Study Locations
More Related Trials
-
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer
NCT03532737 ·Status: RECRUITING ·Phase: PHASE2
-
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
NCT06005324 ·Status: RECRUITING ·Phase: PHASE1
-
App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy
NCT06367257 ·Status: RECRUITING ·Phase: NA
-
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435 ·Status: COMPLETED ·Phase: PHASE2
-
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
NCT06323460 ·Status: RECRUITING ·Phase: PHASE2
-
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
NCT01358097 ·Status: COMPLETED
-
Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo
NCT00258310 ·Status: COMPLETED ·Phase: PHASE2
-
Hypofractionated Radiochemotherapy
NCT06331468 ·Status: RECRUITING ·Phase: PHASE2
-
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
NCT07121595 ·Status: RECRUITING ·Phase: PHASE2
-
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
NCT03383094 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Nasopharyngeal Carcinoma Post IMRT
NCT02597426 ·Status: ACTIVE_NOT_RECRUITING
-
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT03386357 ·Status: TERMINATED ·Phase: PHASE2
-
Cell-free Tumor DNA in Head and Neck Cancer Patients
NCT03942380 ·Status: UNKNOWN ·Phase: NA
-
REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors
NCT03317327 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
NCT00006051 ·Status: COMPLETED ·Phase: PHASE2
-
InductionChemo-Radio-Antibody-Treatment
NCT01181401 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
NCT02383927 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects on Auditory Function of RADiotherapy and Chemotherapy Treatments for Head and Neck Tumours (EARAD)
NCT03914378 ·Status: RECRUITING
-
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
NCT02031250 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial Evaluating Elimination of Radiation Therapy
NCT00593840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca
NCT01530997 ·Status: COMPLETED ·Phase: PHASE2
-
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
NCT03215719 ·Status: RECRUITING ·Phase: PHASE2
-
The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma
NCT04303975 ·Status: UNKNOWN
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
NCT05307939 ·Status: RECRUITING ·Phase: PHASE2
-
Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)
NCT02059668 ·Status: COMPLETED